Circadian Rhythm Genes Are Biomarkers for Predicting Risk of Preterm Birth
|
By LabMedica International staff writers Posted on 17 Aug 2021 |

Structure of CLOCK circadian regulator (courtesy of: Wikimedia Commons)
The CLOCK and CRY2 genes have been identified as useful biomarkers for predicting the likelihood that a pregnant woman will experience a preterm birth.
Previous studies have observed an association between maternal circadian rhythm disruption and preterm birth. However, the underlying molecular mechanisms and the potential of circadian clock genes to serve as predictors of preterm birth remain unexplored.
Investigators at Michigan State University (East Lansing, USA) examined the association of 10 core circadian transcripts in maternal blood with spontaneous preterm births versus full term births using a nested case-control study design. For this study, maternal blood was sampled in trimesters two-three from women with spontaneous preterm births (n = 51) and full term births (n = 106), matched for five demographic variables.
Results revealed that in second trimester maternal blood, only CLOCK and CRY2 transcripts were significantly lower in spontaneous preterm births versus full term. In addition, the investigators identified 98 common pathways that were negatively or positively correlated with CLOCK and CRY2 expression.
CLOCK is a gene encoding a basic helix-loop-helix-PAS transcription factor that is believed to affect both the persistence and period of circadian rhythms. The CLOCK gene plays a major role as an activator of downstream elements in the pathway critical to the generation of circadian rhythms. In mammals, the proteins coded by the CRY1 and CRY2 genes act as light-independent inhibitors of CLOCK-BMAL1 components of the circadian clock.
“We were excited to discover lower mRNA levels in the CRY2 and CLOCK genes,” said senior author Dr. Hanne Hoffmann, assistant professor of animal science at Michigan State University. “Preterm births are common. If we know the mother is at risk for a preterm birth, her doctor can monitor her more closely. If we could measure women’s mRNA levels and tell them for their second or third pregnancies that they are not at risk for a preterm birth because their levels are higher (in a normal/healthy range), that would be such a comfort to the mothers who previously had a preterm birth. If I can help one baby make it to full term who was not supposed to, that would make my day.”
The preterm birth study was published in the June 18, 2021, online edition of the Journal Biology of Reproduction.
Related Links:
Michigan State University
Previous studies have observed an association between maternal circadian rhythm disruption and preterm birth. However, the underlying molecular mechanisms and the potential of circadian clock genes to serve as predictors of preterm birth remain unexplored.
Investigators at Michigan State University (East Lansing, USA) examined the association of 10 core circadian transcripts in maternal blood with spontaneous preterm births versus full term births using a nested case-control study design. For this study, maternal blood was sampled in trimesters two-three from women with spontaneous preterm births (n = 51) and full term births (n = 106), matched for five demographic variables.
Results revealed that in second trimester maternal blood, only CLOCK and CRY2 transcripts were significantly lower in spontaneous preterm births versus full term. In addition, the investigators identified 98 common pathways that were negatively or positively correlated with CLOCK and CRY2 expression.
CLOCK is a gene encoding a basic helix-loop-helix-PAS transcription factor that is believed to affect both the persistence and period of circadian rhythms. The CLOCK gene plays a major role as an activator of downstream elements in the pathway critical to the generation of circadian rhythms. In mammals, the proteins coded by the CRY1 and CRY2 genes act as light-independent inhibitors of CLOCK-BMAL1 components of the circadian clock.
“We were excited to discover lower mRNA levels in the CRY2 and CLOCK genes,” said senior author Dr. Hanne Hoffmann, assistant professor of animal science at Michigan State University. “Preterm births are common. If we know the mother is at risk for a preterm birth, her doctor can monitor her more closely. If we could measure women’s mRNA levels and tell them for their second or third pregnancies that they are not at risk for a preterm birth because their levels are higher (in a normal/healthy range), that would be such a comfort to the mothers who previously had a preterm birth. If I can help one baby make it to full term who was not supposed to, that would make my day.”
The preterm birth study was published in the June 18, 2021, online edition of the Journal Biology of Reproduction.
Related Links:
Michigan State University
Latest Microbiology News
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreMolecular Diagnostics
view channel
New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
Prenatal genetic screening often requires multiple tests, blood draws, and follow-up appointments, delaying access to clinically relevant information. Early, consolidated insights may help clinicians coordinate... Read more
Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more
Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read moreHematology
view channel
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read moreImmunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more








